The fastest-growing segment in the U.S. diabetes market is the FGM market, which has increased dramatically in value. The high level of growth was attributed to the commercial launch of FGM. Abbott received FDA approval for FreeStyle? Libre and for FreeStyle? Libre 14 Day. The FGM market has experienced significant growth in international markets since it was first commercially launched in Europe almost ten years ago. Growth in the U.S. market is expected to follow a similar trend, primarily attributed to an expanding installed base of FGM users.
The full report suite on the U.S. market for diabetes monitoring, treatment and drug delivery includes blood glucose meters, blood glucose test strips, lancets, continuous glucose monitoring (CGM), flash glucose monitoring (FGM), insulin, insulin pens, insulin syringes and insulin pumps.